City Therapeutics has finalised its IPO, raising $200 million for a pipeline of RNA interference therapies headed by a novel anticoagulant.

Arrowhead reported interim healthy-volunteer data showing up to 73% mean CSF total tau reduction, while clinical benefit in Alzheimer's disease remains untested.

CITY THERAPEUTICS, INC. filed for an IPO

Biotech financings this week include SanegeneBio's Lilly-backed $110m Series B, with Sidera, D3 Bio, BlossomHill, and Prolynx also raising new funds.

This study uncovers the structural mechanism by which the RNA-induced silencing complex (RISC), a key effector of RNA interference, is assembled in human cells. RISC is composed of an Argonaute (AGO) protein bound to a small RNA, such as a microRNA or siRNA, which guides gene silencing. Although it has long been known that molecular chaperones like HSP70 and HSP90 are required for loading small RNA duplexes onto AGO proteins, the precise structural process remained unclear. Using cryogenic electron microscopy, the authors resolved the structure of a human AGO–HSP90–p23 complex, termed the AGO maturation complex (AMC). This complex captures AGO in an open, RNA-free conformation in which its domains are separated and stabilized by the HSP90 dimer. The arrangement exposes a positively charged cleft that allows binding of small RNA duplexes. Importantly, the study shows that AGO folding and maturation are not driven by single-stranded RNA alone but require a double-stranded RNA duplex with a 5′ phosphate, which acts as a cofactor to promote proper structural assembly. The findings demonstrate that the chaperone system does more than stabilize proteins—it actively orchestrates AGO folding and RNA loading. The RNA duplex itself plays a previously unrecognized role as a chaperone-like element guiding protein assembly. This mechanism was validated using biochemical reconstitution experiments showing that the purified AMC can recapitulate RISC assembly in vitro. Overall, the research provides a detailed molecular explanation for how RISC is formed and highlights the coordinated action of chaperones and RNA substrates in regulating gene silencing machinery. These insights also have implications for improving the design of RNA-based therapeutics, such as siRNA drugs, by revealing structural requirements for efficient AGO loading.

Scientists discovered stable RNA on plant leaves that can regulate microbes, revealing a new layer of plant-environment interaction.

Discover key insights into the Global Gene Silencing Market. Explore trends, growth drivers, and key players shaping the future of gene silencing technologies by 2025.

Researchers at Martin Luther University have developed groundbreaking RNA-based agents that offer high levels of protection against the Cucumber mosaic virus, a major agricultural threat. These agents...